Home » Topics » BioWorld Science

BioWorld Science
RSS

Elastrin Therapeutics closes funding round to advance development of lead candidate

April 8, 2022

1st Bio Therapeutics presents new protein kinase inhibitors

April 8, 2022

Novel HlyU inhibitor VM-17 attenuates the virulence of V. vulnificus

April 8, 2022

Researchers in China find evidence in mice that bacteria in tumors help cancer cells metastasize

April 8, 2022

PX-478 prevents rise of glycemia and improves beta-cell function in models diabetes

April 8, 2022

Jazz and Werewolf announce global license and collaboration agreement to develop WTX-613

April 8, 2022

Small molecule inhibitors of natural killer group 2D identified at Janssen

April 8, 2022

GPR30 is a therapeutic target in triple-negative inflammatory breast cancer

April 8, 2022

IKZF1 gain-of-function variants tied to T/B cell-related immune dysregulation

April 7, 2022

Emergex collaborates with nonprofit organization to advance yellow fever booster vaccine candidate

April 7, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...